FDA places hold on Abeona late-stage study

Abeona Therapeutics announced that the FDA has placed a clinical hold on its planned Phase 3 clinical trial evaluating autologous cell therapy EB-101 in patients with recessive dystrophic epidermolysis bullosa.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news